Update on pipeline - new pharmaceutical candidate Lu AA37096 enters Lundbeck's development pipeline

Lu AA37096 has been discovered based on findings with the unique
mechanism of action of escitalopram (Cipralex®) but incorporates
effects on a number of additional targets in the brain. Lu AA37096
has shown very convincing effects in animal models of mood disorders
as well as in pain models."Focus at Lundbeck Research is to discover innovative compounds that
address unmet needs for patients. Lu AA37096 is an example of a new
generation of compounds with a great potential within mood disorders
and other indications for which preclinical research has demonstrated
significant efficacy," says Peter Høngaard Andersen, Head of Research
at Lundbeck.

At the same time Lundbeck has decided to discontinue further
development of Lu AA44608 in clinical phase I for the potential
treatment of mood disorders.

The content of this release have no influence on the Lundbeck Group's
financial result for 2007 being presented on 4 March 2008. On the
same occasion Lundbeck will present the expectations for the
financial result for 2008.



Lundbeck contacts


Investors:                    Media:

Jacob Tolstrup                Anders Schroll
Director, Corporate Reporting Head of Communication
+45 36 43 30 79               +45 36 43 20 81

Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26


                      ________________________

Stock Exchange Release No 318 - 3 January 2008

About Lundbeck
H. Lundbeck A/S is an international pharmaceutical company engaged in
the research and development, production, marketing and sale of drugs
for the treatment of psychiatric and neurological disorders. In 2006,
the company's revenue was DKK 9.2 billion (approximately EUR 1.2
billion or USD 1.6 billion). The number of employees is approximately
5,300 globally. For further information, please visit
www.lundbeck.com